Tissue Engineering
Get Tissue Engineering essential facts below. View Videos or join the Tissue Engineering discussion. Add Tissue Engineering to your PopFlock.com topic list for future reference or share this resource on social media.
Tissue Engineering

A simplified overview of the general methods used in regenerative medicine

Tissue engineering is the use of a combination of cells, engineering, and materials methods, and suitable biochemical and physicochemical factors to improve or replace biological tissues. Tissue engineering involves the use of a tissue scaffold for the formation of new viable tissue for a medical purpose. While it was once categorized as a sub-field of biomaterials, having grown in scope and importance it can be considered as a field in its own.

What tissue engineering is and how it works

While most definitions of tissue engineering cover a broad range of applications, in practice the term is closely associated with applications that repair or replace portions of or whole tissues (i.e., bone, cartilage,[1]blood vessels, bladder, skin, muscle etc.). Often, the tissues involved require certain mechanical and structural properties for proper functioning. The term has also been applied to efforts to perform specific biochemical functions using cells within an artificially-created support system (e.g. an artificial pancreas, or a bio artificial liver). The term regenerative medicine is often used synonymously with tissue engineering, although those involved in regenerative medicine place more emphasis on the use of stem cells or progenitor cells to produce tissues.

Overview

Micro-mass cultures of C3H-10T1/2 cells at varied oxygen tensions stained with Alcian blue

A commonly applied definition of tissue engineering, as stated by Langer[2] and Vacanti,[3] is "an interdisciplinary field that applies the principles of engineering and life sciences toward the development of biological substitutes that restore, maintain, or improve [Biological tissue] function or a whole organ".[4] Tissue engineering has also been defined as "understanding the principles of tissue growth, and applying this to produce functional replacement tissue for clinical use".[5] A further description goes on to say that an "underlying supposition of tissue engineering is that the employment of natural biology of the system will allow for greater success in developing therapeutic strategies aimed at the replacement, repair, maintenance, or enhancement of tissue function".[5]

Powerful developments in the multidisciplinary field of tissue engineering have yielded a novel set of tissue replacement parts and implementation strategies. Scientific advances in biomaterials, stem cells, growth and differentiation factors, and biomimetic environments have created unique opportunities to fabricate tissues in the laboratory from combinations of engineered extracellular matrices ("scaffolds"), cells, and biologically active molecules. Among the major challenges now facing tissue engineering is the need for more complex functionality, as well as both functional and biomechanical stability and vascularization in laboratory-grown tissues destined for transplantation. The continued success of tissue engineering and the eventual development of true human replacement parts will grow from the convergence of engineering and basic research advances in tissue, matrix, growth factor, stem cell, and developmental biology, as well as materials science and bioinformatics.

In 2003, the NSF published a report entitled "The Emergence of Tissue Engineering as a Research Field", which gives a thorough description of the history of this field.[6]

Etymology

The historic origins of the term are unclear as the definition of the word has changed throughout the past decades. The term first appeared in a 1984 publication that described the organization of an endothelium-like membrane on the surface of a long-implanted, synthetic ophthalmic prosthesis [7]

The first modern use of the term as recognized today was in 1985 by the researcher, physiologist and bioengineer Y.C Fung of the Engineering Research Center. He proposed the joining of the terms tissue (in reference to the fundamental relationship between cells and organs) and engineering (in reference to the field of modification of said tissues). The term was officially adopted in 1987.[7]

History

Ancient Era (Pre-20th Century)

Human tissue has been a subject of scientific curiosity and exploration for thousands of years.

In Ancient Egypt, physicians studied corpses and living humans in order to understand how to treat wounds. They would graft skin from corpses onto living humans.[7] Mummies were also studied to understand various skin preservation techniques. Surgeries were routinely performed without any prior knowledge of sterilization, immunological responses or skin reactions.

Between 1069 and 664 B.C, various signs of skin grafts and transplants were observed on mummies and corpses of wealthy individuals. A 50- to 60-year-old woman with a visible prosthesis was discovered near the ancient city of Thebes.[8] The prosthetic toe was most likely installed due to a previous fight with diabetes and is displayed in the Cairo Museum.

Between the 1st and 2nd century A.D, the Gallo-Romans developed wrought iron implants in a necropolis at Chantambre.[7]

In 1931, multiple signs of dental implants were discovered in a jaw that belonged to a Mayan woman dating back to 600 AD. This is the earliest evidence of a prior form of tissue engineering in the Americas.[7]

Linen sutures were first designed by early Egyptians while metallic and gold sutures were invented as early as 200 AD. Modern lead wires were invented in 1800 while safer and cheaper silver wires in 1850.[7]

Modern Era (20th and 21st Centuries)

Skin Transplantations

Researchers were studying the immunological basis for the rejection of skin allografts by the early decades of the 20th century, but no significant progress was made in any practical solution. The marked increase in the number of burn victims since World War II for whom a skin allograft was not feasible has provided a renewed impetus for skin replacement research. During this period, the immunologist Peter Medawar contributed to further progress in understanding the immunology of graft rejection.[7]

Kidney Transplantations

In the early part of the 20th century, a number of scientists sporadically experimented with kidney transplantation, but organized renal transplantation attempts only started in the late 1940s. Kolff invented the first dialysis system in the Netherlands during the war years; its architecture was improved at Peter Bent Brigham Hospital in Boston and first used in patients in 1948. The availability of efficient short-term dialysis, in addition, encouraged progress on transplantation, resulting in Murray and colleagues at Brigham and Women's Hospital successfully transplanting a donated kidney from a twin in 1954. Later developments in immunosuppression for transplantation as well as further advancement of the Kolff dialysis system made both methods feasible for extensive, daily use, transforming end-stage renal disease management. Nevertheless, the insufficient availability of transplantation-fitting organs, coupled with knowledge of the dialysis machine's medical limitations, prompted the design of the bioartificial kidney model, which would more closely imitate the kidney's functional roles and thus prevent the destructive symptoms of chronic dialysis.[7]

Liver Transplantations

Starzl performed the first effective liver transplant in 1967, but in the absence of a sufficient supply of transplantable organs, researchers and clinicians have continued to seek alternative approaches to hepatic function replacement. Hemodialysis, hemoperfusion over charcoal or resins, or incapacitated enzymes, plasmapheresis, and plasma exchange are still not biological approaches that have been examined.[7]

Examples

Regenerating a human ear using a scaffold

Cells as building blocks

Stained cells in culture

Tissue engineering utilizes living cells as engineering materials. Examples include using living fibroblasts in skin replacement or repair, cartilage repaired with living chondrocytes, or other types of cells used in other ways.

Cells became available as engineering materials when scientists at Geron Corp. discovered how to extend telomeres in 1998, producing immortalized cell lines.[20][] Before this, laboratory cultures of healthy, noncancerous mammalian cells would only divide a fixed number of times, up to the Hayflick limit, before dying.

Extraction

From fluid tissues such as blood, cells are extracted by bulk methods, usually centrifugation or apheresis. From solid tissues, extraction is more difficult. Usually, the tissue is minced and then digested with the enzymes trypsin or collagenase to remove the extracellular matrix (ECM) that holds the cells. After that, the cells are free floating, and extracted using centrifugation or apheresis.
Digestion with trypsin is very dependent on temperature. Higher temperatures digest the matrix faster but create more damage. Collagenase is less temperature dependent, and damages fewer cells, but takes longer and is a more expensive reagent.

Types of cells

Mouse embryonic stem cells

Cells are often categorized by their source.

Autologous cells are obtained from the same individual to which they will be reimplanted. Autologous cells have the fewest problems with rejection and pathogen transmission, however, in some cases might not be available. For example, in genetic disease suitable autologous cells are not available. Also, very ill or elderly persons, as well as patients suffering from severe burns, may not have sufficient quantities of autologous cells to establish useful cell lines. Moreover, since this category of cells needs to be harvested from the patient, there are also some concerns related to the necessity of performing such surgical operations that might lead to donor site infection or chronic pain. Autologous cells also must be cultured from samples before they can be used: this takes time, so autologous solutions may not be very quick. Recently there has been a trend towards the use of mesenchymal stem cells from bone marrow and fat. These cells can differentiate into a variety of tissue types, including bone, cartilage, fat, and nerve. A large number of cells can be easily and quickly isolated from fat, thus opening the potential for large numbers of cells to be quickly and easily obtained.

Allogeneic cells come from the body of a donor of the same species. While there are some ethical constraints to the use of human cells for in vitro studies, the employment of dermal fibroblasts from human foreskin has been demonstrated to be immunologically safe and thus a viable choice for tissue engineering of skin.

Xenogenic cells are these isolated from individuals of another species. In particular animal cells have been used quite extensively in experiments aimed at the construction of cardiovascular implants.

Syngenic or isogenic cells are isolated from genetically identical organisms, such as twins, clones, or highly inbred research animal models.

Primary cells are from an organism.

Secondary cells are from a cell bank.

Stem cells are undifferentiated cells with the ability to divide in culture and give rise to different forms of specialized cells. According to their source stem cells are divided into "adult" and "embryonic" stem cells, the first class being multipotent and the latter mostly pluripotent; some cells are totipotent, in the earliest stages of the embryo. While there is still a large ethical debate related with the use of embryonic stem cells, it is thought that another alternative source - induced stem cells may be useful for the repair of diseased or damaged tissues, or may be used to grow new organs.

Scaffolds

Scaffolds are materials that have been engineered to cause desirable cellular interactions to contribute to the formation of new functional tissues for medical purposes. Cells are often 'seeded' into these structures capable of supporting three-dimensional tissue formation. Scaffolds mimic the extracellular matrix of the native tissue, recapitulating the in vivo milieu and allowing cells to influence their own microenvironments. They usually serve at least one of the following purposes: allow cell attachment and migration, deliver and retain cells and biochemical factors, enable diffusion of vital cell nutrients and expressed products, exert certain mechanical and biological influences to modify the behaviour of the cell phase.

In 2009, an interdisciplinary team led by the thoracic surgeon Thorsten Walles implanted the first bioartificial transplant that provides an innate vascular network for post-transplant graft supply successfully into a patient awaiting tracheal reconstruction.[21]

This animation of a rotating carbon nanotube shows its 3D structure. Carbon nanotubes are among the numerous candidates for tissue engineering scaffolds since they are biocompatible, resistant to biodegradation and can be functionalized with biomolecules. However, the possibility of toxicity with non-biodegradable nano-materials is not fully understood.[22]

To achieve the goal of tissue reconstruction, scaffolds must meet some specific requirements. High porosity and adequate pore size are necessary to facilitate cell seeding and diffusion throughout the whole structure of both cells and nutrients. Biodegradability is often an essential factor since scaffolds should preferably be absorbed by the surrounding tissues without the necessity of surgical removal. The rate at which degradation occurs has to coincide as much as possible with the rate of tissue formation: this means that while cells are fabricating their own natural matrix structure around themselves, the scaffold is able to provide structural integrity within the body and eventually it will break down leaving the newly formed tissue which will take over the mechanical load. Injectability is also important for clinical uses. Recent research on organ printing is showing how crucial a good control of the 3D environment is to ensure reproducibility of experiments and offer better results.

Materials

Many different materials (natural and synthetic, biodegradable and permanent) have been investigated.[23] Most of these materials have been known in the medical field before the advent of tissue engineering as a research topic, being already employed as bioresorbable sutures. Examples of these materials are collagen and some polyesters.

New biomaterials have been engineered to have ideal properties and functional customization: injectability, synthetic manufacture, biocompatibility, non-immunogenicity, transparency, nano-scale fibers, low concentration, resorption rates, etc. PuraMatrix, originating from the MIT labs of Zhang, Rich, Grodzinsky, and Langer is one of these new biomimetic scaffold families which has now been commercialized.

A commonly used synthetic material is PLA - polylactic acid. This is a polyester which degrades within the human body to form lactic acid, a naturally occurring chemical which is easily removed from the body. Similar materials are polyglycolic acid (PGA) and polycaprolactone (PCL): their degradation mechanism is similar to that of PLA, but they exhibit respectively a faster and a slower rate of degradation compared to PLA. While these materials have well maintained mechanical strength and structural integrity, they exhibit a hydrophobic nature. This hydrophobicity inhibits their biocompatibility, which makes them less effective for in vivo use as tissue scaffolding.[24] In order to fix the lack of biocompatibility, much research has been done to combine these hydrophobic materials with hydrophilic and more biocompatible hydrogels. While these hydrogels have a superior biocompatibility, they lack the structural integrity of PLA, PCL, and PGA. By combining the two different types of materials, researchers are trying to create a synergistic relationship that produces a more biocompatible tissue scaffolding.[25] Scaffolds may also be constructed from natural materials: in particular different derivatives of the extracellular matrix have been studied to evaluate their ability to support cell growth. Proteic materials, such as collagen or fibrin, and polysaccharidic materials, like chitosan[26] or glycosaminoglycans (GAGs), have all proved suitable in terms of cell compatibility, but some issues with potential immunogenicity still remains. Among GAGs hyaluronic acid, possibly in combination with cross linking agents (e.g. glutaraldehyde, water-soluble carbodiimide, etc.), is one of the possible choices as scaffold material. Functionalized groups of scaffolds may be useful in the delivery of small molecules (drugs) to specific tissues. Another form of scaffold under investigation is decellularised tissue extracts whereby the remaining cellular remnants/extracellular matrices act as the scaffold. Recently a range of nanocomposites biomaterials are fabricated by incorporating nanomaterials within the polymeric matrix to engineer bioactive scaffolds.[27]

A 2009 study by Derda et al. aimed to improve in vivo-like conditions for 3D tissue via "stacking and de-stacking layers of paper impregnated with suspensions of cells in extracellular matrix hydrogel, making it possible to control oxygen and nutrient gradients in 3D, and to analyze molecular and genetic responses".[28] It is possible to manipulate gradients of soluble molecules, and to characterize cells in these complex gradients more effectively than conventional 3D cultures based on hydrogels, cell spheroids, or 3D perfusion reactors.[29] Different thicknesses of paper and types of medium can support a variety of experimental environments. Upon deconstruction, these sheets can be useful in cell-based high-throughput screening and drug discovery.[29]

Synthesis

Tissue engineered vascular graft
Tissue engineered heart valve

A number of different methods have been described in the literature for preparing porous structures to be employed as tissue engineering scaffolds. Each of these techniques presents its own advantages, but none are free of drawbacks.

Nanofiber self-assembly

Molecular self-assembly is one of the few methods for creating biomaterials with properties similar in scale and chemistry to that of the natural in vivo extracellular matrix (ECM), a crucial step toward tissue engineering of complex tissues.[30] Moreover, these hydrogel scaffolds have shown superiority in in vivo toxicology and biocompatibility compared to traditional macroscaffolds and animal-derived materials.

Textile technologies

These techniques include all the approaches that have been successfully employed for the preparation of non-woven meshes of different polymers. In particular, non-woven polyglycolide structures have been tested for tissue engineering applications: such fibrous structures have been found useful to grow different types of cells. The principal drawbacks are related to the difficulties in obtaining high porosity and regular pore size.

Solvent casting and particulate leaching

Solvent casting and particulate leaching (SCPL) allows for the preparation of structures with regular porosity, but with limited thickness. First, the polymer is dissolved into a suitable organic solvent (e.g. polylactic acid could be dissolved into dichloromethane), then the solution is cast into a mold filled with porogen particles. Such porogen can be an inorganic salt like sodium chloride, crystals of saccharose, gelatin spheres or paraffin spheres. The size of the porogen particles will affect the size of the scaffold pores, while the polymer to porogen ratio is directly correlated to the amount of porosity of the final structure. After the polymer solution has been cast the solvent is allowed to fully evaporate, then the composite structure in the mold is immersed in a bath of a liquid suitable for dissolving the porogen: water in the case of sodium chloride, saccharose and gelatin or an aliphatic solvent like hexane for use with paraffin. Once the porogen has been fully dissolved, a porous structure is obtained. Other than the small thickness range that can be obtained, another drawback of SCPL lies in its use of organic solvents which must be fully removed to avoid any possible damage to the cells seeded on the scaffold.

Gas foaming

To overcome the need to use organic solvents and solid porogens, a technique using gas as a porogen has been developed. First, disc-shaped structures made of the desired polymer are prepared by means of compression molding using a heated mold. The discs are then placed in a chamber where they are exposed to high pressure CO2 for several days. The pressure inside the chamber is gradually restored to atmospheric levels. During this procedure the pores are formed by the carbon dioxide molecules that abandon the polymer, resulting in a sponge-like structure. The main problems resulting from such a technique are caused by the excessive heat used during compression molding (which prohibits the incorporation of any temperature labile material into the polymer matrix) and by the fact that the pores do not form an interconnected structure.

Emulsification freeze-drying

This technique does not require the use of a solid porogen like SCPL. First, a synthetic polymer is dissolved into a suitable solvent (e.g. polylactic acid in dichloromethane) then water is added to the polymeric solution and the two liquids are mixed in order to obtain an emulsion. Before the two phases can separate, the emulsion is cast into a mold and quickly frozen by means of immersion into liquid nitrogen. The frozen emulsion is subsequently freeze-dried to remove the dispersed water and the solvent, thus leaving a solidified, porous polymeric structure. While emulsification and freeze-drying allow for a faster preparation when compared to SCPL (since it does not require a time-consuming leaching step), it still requires the use of solvents. Moreover, pore size is relatively small and porosity is often irregular. Freeze-drying by itself is also a commonly employed technique for the fabrication of scaffolds. In particular, it is used to prepare collagen sponges: collagen is dissolved into acidic solutions of acetic acid or hydrochloric acid that are cast into a mold, frozen with liquid nitrogen and then lyophilized.

Thermally induced phase separation

Similar to the previous technique, the TIPS phase separation procedure requires the use of a solvent with a low melting point that is easy to sublime. For example, dioxane could be used to dissolve polylactic acid, then phase separation is induced through the addition of a small quantity of water: a polymer-rich and a polymer-poor phase are formed. Following cooling below the solvent melting point and some days of vacuum-drying to sublime the solvent, a porous scaffold is obtained. Liquid-liquid phase separation presents the same drawbacks of emulsification/freeze-drying.[31]

Electrospinning

Electrospinning is a highly versatile technique that can be used to produce continuous fibers from submicrometer to nanometer diameters. In a typical electrospinning set-up, a solution is fed through a spinneret and a high voltage is applied to the tip. The buildup of electrostatic repulsion within the charged solution, causes it to eject a thin fibrous stream. A mounted collector plate or rod with an opposite or grounded charge draws in the continuous fibers, which arrive to form a highly porous network. The primary advantages of this technique are its simplicity and ease of variation. At a laboratory level, a typical electrospinning set-up only requires a high voltage power supply (up to 30 kV), a syringe, a flat tip needle, and a conducting collector. For these reasons, electrospinning has become a common method of scaffold manufacture in many labs. By modifying variables such as the distance to collector, magnitude of applied voltage, or solution flow rate--researchers can dramatically change the overall scaffold architecture.

Historically, research on electrospun fibrous scaffolds dates back to at least the late 1980s when Simon showed that electrospinning could be used to produced nano- and submicron-scale fibrous scaffolds from polymer solutions specifically intended for use as in vitro cell and tissue substrates. This early use of electrospun lattices for cell culture and tissue engineering showed that various cell types would adhere to and proliferate upon polycarbonate fibers. It was noted that as opposed to the flattened morphology typically seen in 2D culture, cells grown on the electrospun fibers exhibited a more rounded 3-dimensional morphology generally observed of tissues in vivo.[32]

CAD/CAM technologies

Because most of the above techniques are limited when it comes to the control of porosity and pore size, computer assisted design and manufacturing techniques have been introduced to tissue engineering. First, a three-dimensional structure is designed using CAD software. The porosity can be tailored using algorithms within the software.[33] The scaffold is then realized by using ink-jet printing of polymer powders or through Fused Deposition Modeling of a polymer melt.[34]

A 2011 study by El-Ayoubi et al. investigated "3D-plotting technique to produce (biocompatible and biodegradable) poly-L-Lactide macroporous scaffolds with two different pore sizes" via solid free-form fabrication (SSF) with computer-aided-design (CAD), to explore therapeutic articular cartilage replacement as an "alternative to conventional tissue repair".[35] The study found the smaller the pore size paired with mechanical stress in a bioreactor (to induce in vivo-like conditions), the higher the cell viability in potential therapeutic functionality via decreasing recovery time and increasing transplant effectiveness.[35]

Laser-assisted bioprinting

In a 2012 study,[36] Koch et al. focused on whether Laser-assisted BioPrinting (LaBP) can be used to build multicellular 3D patterns in natural matrix, and whether the generated constructs are functioning and forming tissue. LaBP arranges small volumes of living cell suspensions in set high-resolution patterns.[36] The investigation was successful, the researchers foresee that "generated tissue constructs might be used for in vivo testing by implanting them into animal models" (14). As of this study, only human skin tissue has been synthesized, though researchers project that "by integrating further cell types (e.g. melanocytes, Schwann cells, hair follicle cells) into the printed cell construct, the behavior of these cells in a 3D in vitro microenvironment similar to their natural one can be analyzed", which is useful for drug discovery and toxicology studies.[36]

Self-assembled recombinant spider silk nanomembranes

Gustafsson et al.[37] demonstrated free-standing, bioactive membranes of cm-sized area, but only 250 nm thin, that were formed by self-assembly of spider silk at the interface of an aqueous solution. The membranes uniquely combine nanoscale thickness, biodegradability, ultrahigh strain and strength, permeability to proteins and promote rapid cell adherence and proliferation. They demonstrated growing a coherent layer of keratinocytes.

Assembly methods

One of the continuing, persistent problems with tissue engineering is mass transport limitations. Engineered tissues generally lack an initial blood supply, thus making it difficult for any implanted cells to obtain sufficient oxygen and nutrients to survive, or function properly.

Self-assembly

Self-assembly methods have been shown to be promising methods for tissue engineering. Self-assembly methods have the advantage of allowing tissues to develop their own extracellular matrix, resulting in tissue that better recapitulates biochemical and biomechanical properties of native tissue. Self-assembling engineered articular cartilage was introduced by Jerry Hu and Kyriacos A. Athanasiou in 2006[38] and applications of the process have resulted in engineered cartilage approaching the strength of native tissue.[39] Self-assembly is a prime technology to get cells grown in a lab to assemble into three-dimensional shapes. To break down tissues into cells, researchers first have to dissolve the extracellular matrix that normally binds them together. Once cells are isolated, they must form the complex structures that make up our natural tissues.

Liquid-based template assembly

The air-liquid surface established by Faraday waves is explored as a template to assemble biological entities for bottom-up tissue engineering. This liquid-based template can be dynamically reconfigured in a few seconds, and the assembly on the template can be achieved in a scalable and parallel manner. Assembly of microscale hydrogels, cells, neuron-seeded micro-carrier beads, cell spheroids into various symmetrical and periodic structures was demonstrated with good cell viability. Formation of 3D neural network was achieved after 14-day tissue culture.[40]

Additive manufacturing

It might be possible to print organs, or possibly entire organisms using additive manufacturing techniques. A recent innovative method of construction uses an ink-jet mechanism to print precise layers of cells in a matrix of thermoreversible gel. Endothelial cells, the cells that line blood vessels, have been printed in a set of stacked rings. When incubated, these fused into a tube.[34][41]

The field of three-dimensional and highly accurate models of biological systems is pioneered by multiple projects and technologies including a rapid method for creating tissues and even whole organs involve a 3D printer that can print the scaffolding and cells layer by layer into a working tissue sample or organ. The device is presented in a TED talk by Dr. Anthony Atala, M.D. the Director of the Wake Forest Institute for Regenerative Medicine, and the W.H. Boyce Professor and Chair of the Department of Urology at Wake Forest University, in which a kidney is printed on stage during the seminar and then presented to the crowd.[42][43][44] It is anticipated that this technology will enable the production of livers in the future for transplantation and theoretically for toxicology and other biological studies as well.

Recently Multi-Photon Processing (MPP) was employed for in vivo experiments by engineering artificial cartilage constructs. An ex vivo histological examination showed that certain pore geometry and the pre-growing of chondrocytes (Cho) prior to implantation significantly improves the performance of the created 3D scaffolds. The achieved biocompatibility was comparable to the commercially available collagen membranes. The successful outcome of this study supports the idea that hexagonal-pore-shaped hybrid organic-inorganic microstructured scaffolds in combination with Cho seeding may be successfully implemented for cartilage tissue engineering.[45]

Scaffolding

In 2013, using a 3-d scaffolding of Matrigel in various configurations, substantial pancreatic organoids was produced in vitro. Clusters of small numbers of cells proliferated into 40,000 cells within one week. The clusters transform into cells that make either digestive enzymes or hormones like insulin, self-organizing into branched pancreatic organoids that resemble the pancreas.[46]

The cells are sensitive to the environment, such as gel stiffness and contact with other cells. Individual cells do not thrive; a minimum of four proximate cells was required for subsequent organoid development. Modifications to the medium composition produced either hollow spheres mainly composed of pancreatic progenitors, or complex organoids that spontaneously undergo pancreatic morphogenesis and differentiation. Maintenance and expansion of pancreatic progenitors require active Notch and FGF signaling, recapitulating in vivo niche signaling interactions.[47]

The organoids were seen as potentially offering mini-organs for drug testing and for spare insulin-producing cells.[46]

Tissue culture

In many cases, creation of functional tissues and biological structures in vitro requires extensive culturing to promote survival, growth and inducement of functionality. In general, the basic requirements of cells must be maintained in culture, which include oxygen, pH, humidity, temperature, nutrients and osmotic pressure maintenance.

Tissue engineered cultures also present additional problems in maintaining culture conditions. In standard cell culture, diffusion is often the sole means of nutrient and metabolite transport. However, as a culture becomes larger and more complex, such as the case with engineered organs and whole tissues, other mechanisms must be employed to maintain the culture, such as the creation of capillary networks within the tissue.

Bioreactor for cultivation of vascular grafts

Another issue with tissue culture is introducing the proper factors or stimuli required to induce functionality. In many cases, simple maintenance culture is not sufficient. Growth factors, hormones, specific metabolites or nutrients, chemical and physical stimuli are sometimes required. For example, certain cells respond to changes in oxygen tension as part of their normal development, such as chondrocytes, which must adapt to low oxygen conditions or hypoxia during skeletal development. Others, such as endothelial cells, respond to shear stress from fluid flow, which is encountered in blood vessels. Mechanical stimuli, such as pressure pulses seem to be beneficial to all kind of cardiovascular tissue such as heart valves, blood vessels or pericardium.

Bioreactors

A bioreactor in tissue engineering, as opposed to industrial bioreactors, is a device that attempts to simulate a physiological environment in order to promote cell or tissue growth in vitro. A physiological environment can consist of many different parameters such as temperature and oxygen or carbon dioxide concentration but can extend to all kinds of biological, chemical or mechanical stimuli. Therefore, there are systems that may include the application of forces or stresses to the tissue or even of electric current in two- or three-dimensional setups.

In academic and industry research facilities, it is typical for bioreactors to be developed to replicate the specific physiological environment of the tissue being grown (e.g., flex and fluid shearing for heart tissue growth).[48] Several general-use and application-specific bioreactors are also commercially available, and may provide static chemical stimulation or combination of chemical and mechanical stimulation.

There are a variety of bioreactors designed for 3D cell cultures. There are small plastic cylindrical chambers, as well as glass chambers, with regulated internal humidity and moisture specifically engineered for the purpose of growing cells in three dimensions.[49] The bioreactor uses bioactive synthetic materials such as polyethylene terephthalate membranes to surround the spheroid cells in an environment that maintains high levels of nutrients.[29][50] They are easy to open and close, so that cell spheroids can be removed for testing, yet the chamber is able to maintain 100% humidity throughout.[51] This humidity is important to achieve maximum cell growth and function. The bioreactor chamber is part of a larger device that rotates to ensure equal cell growth in each direction across three dimensions.[51]

QuinXell Technologies now under Quintech Life Sciences from Singapore has developed a bioreactor known as the TisXell Biaxial Bioreactor which is specially designed for the purpose of tissue engineering. It is the first bioreactor in the world to have a spherical glass chamber with biaxial rotation; specifically to mimic the rotation of the fetus in the womb; which provides a conducive environment for the growth of tissues.[52]

MC2 Biotek has also developed a bioreactor known as ProtoTissue[49] that uses gas exchange to maintain high oxygen levels within the cell chamber; improving upon previous bioreactors, because the higher oxygen levels help the cell grow and undergo normal cell respiration.[53]

Long fiber generation

In 2013, a group from the University of Tokyo developed cell laden fibers up to a meter in length and on the order of 100 µm in size.[54] These fibers were created using a microfluidic device that forms a double coaxial laminar flow. Each 'layer' of the microfluidic device (cells seeded in ECM, a hydrogel sheath, and finally a calcium chloride solution). The seeded cells culture within the hydrogel sheath for several days, and then the sheath is removed with viable cell fibers. Various cell types were inserted into the ECM core, including myocytes, endothelial cells, nerve cell fibers, and epithelial cell fibers. This group then showed that these fibers can be woven together to fabricate tissues or organs in a mechanism similar to textile weaving. Fibrous morphologies are advantageous in that they provide an alternative to traditional scaffold design, and many organs (such as muscle) are composed of fibrous cells.

Bioartificial organs

An artificial organ is a man-made device that is implanted or integrated into a human to replace a natural organ, for the purpose of restoring a specific function or a group of related functions so the patient may return to normal life as soon as possible. The replaced function doesn't necessarily have to be related to life support but often is. The ultimate goal of tissue engineering as a discipline is to allow both 'off the shelf' bioartificial organs and regeneration of injured tissue in the body. In order to successfully create bioartificial organs from patients stem cells, researchers continue to make improvements in the generation of complex tissues by tissue engineering. For example, much research is aimed at understanding nanoscale cues present in a cell's microenvironment.[30]

Biomimetics

Biomimetics is a field that aims to produce materials and systems that replicate those present in nature.[55] In the context of tissue engineering, this is a common approach used by engineers to create materials for these applications that are comparable to native tissues in terms of their structure, properties, and biocompatibility. Material properties are largely dependent on physical, structural, and chemical characteristics of that material. Subsequently, a biomimetic approach to system design will become significant in material integration, and a sufficient understanding of biological processes and interactions will be necessary. Replication of biological systems and processes may also be used in the synthesis of bio-inspired materials to achieve conditions that produce the desired biological material. Therefore, if a material is synthesized having the same characteristics of biological tissues both structurally and chemically, then ideally the synthesized material will have similar properties. This technique has an extensive history originating from the idea of using natural phenomenon as design inspiration for solutions to human problems. Many modern advancements in technology have been inspired by nature and natural systems, including aircraft, automobiles, architecture, and even industrial systems. Advancements in nanotechnology initiated the application of this technique to micro- and nano-scale problems, including tissue engineering. This technique has been used to develop synthetic bone tissues, vascular technologies, scaffolding materials and integration techniques, and functionalized nanoparticles.[55]

Constructing neural networks in soft material

In 2018, scientists at Brandeis University reported their research on soft material embedded with chemical networks which can mimic the smooth and coordinated behavior of neural tissue. This research was funded by the U.S. Army Research Laboratory.[56] The researchers presented an experimental system of neural networks, theoretically modeled as reaction-diffusion systems. Within the networks was an array of patterned reactors, each performing the Belousov-Zhabotinsky (BZ) reaction. These reactors could function on a nanoliter scale.[57]

The researchers state that the inspiration for their project was the movement of the blue ribbon eel. The eel's movements are controlled by electrical impulses determined by a class of neural networks called the central pattern generator.  Central Pattern Generators function within the autonomic nervous system to control bodily functions such as respiration, movement, and peristalsis.[58]

Qualities of the reactor that were designed were the network topology, boundary conditions, initial conditions, reactor volume, coupling strength, and the synaptic polarity of the reactor (whether its behavior is inhibitory or excitatory).[58] A BZ emulsion system with a solid elastomer polydimethylsiloxane (PDMS) was designed. Both light and bromine permeable PDMS have been reported as viable methods to create a pacemaker for neural networks.[57]

Market

The history of the tissue engineering market can be divided into three major parts. The time before the crash of the biotech market in the early 2000s, the crash and the time afterward.

Beginning

Most early progress in tissue engineering research was done in the US. This is due to less strict regulations regarding stem cell research and more available funding than in other countries. This leads to the creation of academic startups many of them coming from Harvard or MIT. Examples are BioHybridTechnologies whose founder, Bill Chick, went to Harvard Medical School and focused on the creation of artificial pancreas. Another example would be Organogenesis Inc. whose founder went to MIT and worked on skin engineering products. Other companies with links to the MIT are TEI Biosciences, Therics and Guilford Pharmaceuticals.[6] The renewed interest in biotechnologies in the 1980s leads to many private investors investing in these new technologies even though the business models of these early startups were often not very clear and did not present a path to long term profitability.[59] Government sponsors were more restraint in their funding as tissue engineering was considered a high-risk investment.[6]

In the UK the market got off to a slower start even though the regulations on stem cell research were not strict as well. This is mainly due to more investors being less willing to invest in these new technologies which were considered to be high-risk investments.[59] Another problem faced by British companies was getting the NHS to pay for their products. This especially because the NHS runs a cost-effectiveness analysis on all supported products. Novel technologies often do not do well in this respect.[59]

In Japan, the regulatory situation was quite different. First cell cultivation was only allowed in a hospital setting and second academic scientists employed by state-owned universities were not allowed outside employment until 1998. Moreover, the Japanese authorities took longer to approve new drugs and treatments than there US and European counterparts.[59]

For these reasons in the early days of the Japanese market, the focus was mainly on getting products that were already approved elsewhere in Japan and selling them. Contrary to the US market the early actors in Japan were mainly big firms or sub-companies of such big firms, such as J-TEC, Menicon and Terumo, and not small startups.[59] After regulatory changes in 2014, which allowed cell cultivation outside of a hospital setting, the speed of research in Japan increased and Japanese companies also started to develop their own products.[59]

Japanese companies, such as ReproCell and iPS Academia Japan, are currently working on iPS cell-related products.[59]

Crash

Soon after the big boom, the first problems started to appear. There were problems getting products approved by the FDA and if they got approved there were often difficulties in getting insurance providers to pay for the products and getting it accepted by health care providers.[59][60]

For example, Organogenesis ran into problems marketing its product and integrating its product in the health system. This partially due to the difficulties of handling living cells and the increased difficulties faced by physicians in using these products over conventional methods.[59]

Another example would be Advanced Tissue Sciences Dermagraft skin product which could not create a high enough demand without reimbursements from insurance providers. Reasons for this were the price of 4000$ and the circumstance that Additionally Advanced Tissue Sciences struggled to get their product known by physicians.[59]

The above examples demonstrate how companies struggled to make profit. This, in turn, lead investors to lose patience and stoping further funding. In consequence, several Tissue Engineering companies such as Organogenesis and Advanced Tissue Sciences filed for bankruptcy in the early 2000s. At this time, these were the only ones having commercial skin products on the market.[60]

Reemergence

The technologies of the bankrupt or struggling companies were often bought by other companies which continued the development under more conservative business models.[60] Examples of companies who sold their products after folding were Curis[60] and Intercytex.[59]

Many of the companies abandoned their long term goals of developing fully functional organs in favour of products and technologies that could turn a profit in the short run.[59] Examples of these kinds of products are products in the cosmetic and testing industry.

In other cases such as in the case of Advanced Tissue Sciences, the founders started new companies.[59]

In the 2010s the regulatory framework also started to facilitate faster time to market especially in the USA as new centres and pathways were created by the FDA specifically aimed at products coming from living cells such as the Center for Biologics Evaluation and Research.[59]

The first tissue engineering products started to get commercially profitable in the 2010s.[60]

Regulation

In Europe, regulation is currently split into three areas of regulation: medical devices, medicinal products, and biologics. Tissue Engineering products are often of hybrid nature, as they are often composed of cells and a supporting structure. While some products can be approved as medicinal products, others need to gain approval as medical devices.[61] Derksen explains in her thesis that Tissue Engineering researchers are sometimes confronted with regulation that does not fit the characteristics of Tissue Engineering.[62]

New regulatory regimes have been observed in Europe that tackle these issues.[63] An explanation for the difficulties in finding regulatory consensus in this matter is given by a survey conducted in the UK.[61] The authors attribute these problems to the close relatedness and overlap with other technologies such as xenotransplantation. It can therefore not be handled separately by regulatory bodies.[61] Regulation is further complicated by the ethical controversies associated with this and related fields of research (e.g. stem cells controversy, ethics of organ transplantation). The same survey as mentioned above [61] shows on the example of autologous cartilage transplantation that a specific technology can be regarded as 'pure' or 'polluted' by the same social actor.

Two regulatory movements are most relevant to tissue engineering in the European Union. These are the Directive on standards of quality and safety for the sourcing and processing of human tissues [64] which was adopted by the European Parliament in 2004 and a proposed cells and the Human Tissue- Engineered Products regulation. The latter was developed under the abscise of the European Commission DG Enterprise and presented in Brussels in 2004.[65]

See also

[66]

Notes

  1. ^ Whitney G. A.; Jayaraman K.; Dennis J. E.; Mansour J. M. (2014). "Scaffold-free cartilage subjected to frictional shear stress demonstrates damage by cracking and surface peeling". J Tissue Eng Regen Med. 11 (2): 412-424. doi:10.1002/term.1925. PMC 4641823. PMID 24965503.
  2. ^ "Langer Lab: Professor Robert Langer".
  3. ^ "The Laboratory for Tissue Engineering and Organ Fabrication - Massachusetts General Hospital, Boston, MA".
  4. ^ Langer R; Vacanti JP (May 1993). "Tissue engineering". Science. 260 (5110): 920-6. Bibcode:1993Sci...260..920L. doi:10.1126/science.8493529. PMID 8493529.
  5. ^ a b MacArthur BD; Oreffo RO (January 2005). "Bridging the gap". Nature. 433 (7021): 19. Bibcode:2005Natur.433...19M. doi:10.1038/433019a. PMID 15635390. S2CID 2683429.
  6. ^ a b c "NSF: Abt Report on "The Emergence of Tissue Engineering as a Research Field"".
  7. ^ a b c d e f g h i Viola, Jessica; Lal, Bhavya; Grad, Oren (14 October 2003). "The Emergence of Tissue Engineering as a Research Field" (PDF). ABT Associates Inc.
  8. ^ Himanshu, Kaul; Ventikos, Yiannis (2015). "On the Genealogy of tissue engineering and regenerative medecine". Tissue Engineering. Part B, Reviews. 21, 2 (2): 203-217. doi:10.1089/ten.TEB.2014.0285. PMC 4390213. PMID 25343302.
  9. ^ "Anthony J. Atala, MD, Urology".
  10. ^ "Doctors grow organs from patients' own cells". CNN. 3 April 2006.
  11. ^ Simonite, Tom (5 July 2006). "Lab-grown cartilage fixes damaged knees". New Scientist.
  12. ^ Whitney GA (August 2012). "Methods for Producing Scaffold-Free Engineered Cartilage Sheets from Auricular and Articular Chondrocyte Cell Sources and Attachment to Porous Tantalum". BioResearch Open Access. 1 (4): 157-165. doi:10.1089/biores.2012.0231. PMC 3559237. PMID 23514898.
  13. ^ Macchiarini P; Jungebluth P; Go T; et al. (December 2008). "Clinical transplantation of a tissue-engineered airway". Lancet. 372 (9655): 2023-30. doi:10.1016/S0140-6736(08)61598-6. PMID 19022496. S2CID 13153058.
  14. ^ Zilla, Peter; Howard Greisler (1999). Tissue Engineering Of Vascular Prosthetic Grafts. R.G. Landes Company. ISBN 978-1-57059-549-3.
  15. ^ "Tissue Engineering".
  16. ^ "Bone in a bottle: Attempts to create artificial bone marrow have failed until now". The Economist. 7 January 2009.
  17. ^ Choi, Charles Q. (9 November 2009). "Artificial Penis Tissue Proves Promising in Lab Tests". Live Science.
  18. ^ "Epistem.co.uk can create foreskin". Archived from the original on 22 October 2013.
  19. ^ "Foregen.org".
  20. ^ Bodnar, A. G.; Ouellette, M.; Frolkis, M.; Holt, S. E.; Chiu, C. P.; Morin, G. B.; Harley, C. B.; Shay, J. W.; Lichtsteiner, S. (16 January 1998). "Extension of life-span by introduction of telomerase into normal human cells". Science. 279 (5349): 349-352. Bibcode:1998Sci...279..349B. doi:10.1126/science.279.5349.349. ISSN 0036-8075. PMID 9454332.
  21. ^ Mertsching H, Schanz J, Steger V, Schandar M, Schenk M, Hansmann J, Dally I, Friedel G, Walles T. Generation and transplantation of an autologous vascularized bioartificial human tissue. Transplantation. 2009; 88: 203-10.
  22. ^ Newman, Peter; Minett, Andrew; Ellis-Behnke, Rutledge; Zreiqat, Hala (November 2013). "Carbon nanotubes: their potential and pitfalls for bone tissue regeneration and engineering". Nanomedicine: Nanotechnology, Biology and Medicine. 9 (8): 1139-1158. doi:10.1016/j.nano.2013.06.001. PMID 23770067.
  23. ^ Qun Wang, ed. (2017). Smart Materials for Tissue Engineering: Fundamental Principles. Cambridge: Royal Society of Chemistry.
  24. ^ Wang, Jin-Yang; Wang, Kai; Gu, Xi; Luo, Ying (2016). "Polymerization of Hydrogel Network on Microfiber Surface: Synthesis of Hybrid Water-Absorbing Matrices for Biomedical Applications". ACS Biomaterials Science & Engineering. 2 (6): 887-892. doi:10.1021/acsbiomaterials.6b00143. ISSN 2373-9878.
  25. ^ Bosworth, Lucy A.; Turner, Lesley-Anne; Cartmell, Sarah H. (April 2013). "State of the art composites comprising electrospun fibres coupled with hydrogels: a review". Nanomedicine: Nanotechnology, Biology and Medicine. 9 (3): 322-335. doi:10.1016/j.nano.2012.10.008. ISSN 1549-9634. PMID 23178282.
  26. ^ Hwa Park Jung; Schwartz Zvi; Olivares-Navarrete Rene; Boyan Barbara D.; Tannenbaum Rina (2011). "Enhancement of surface wettability via the modification of microstructured titanium implant surfaces with polyelectrolytes". Langmuir. 27 (10): 5976-5985. doi:10.1021/la2000415. PMC 4287413. PMID 21513319.
  27. ^ Gaharwar, AK; Peppas, NA; Khademhosseini, A (March 2014). "Nanocomposite hydrogels for biomedical applications". Biotechnology and Bioengineering. 111 (3): 441-53. doi:10.1002/bit.25160. PMC 3924876. PMID 24264728.
  28. ^ Ratmir D.; et al. (2009). "Paper-Supported 3D Cell Culture for Tissue-Based Bioassays". Proceedings of the National Academy of Sciences of the United States of America. 106 (44): 18457-18462. Bibcode:2009PNAS..10618457D. doi:10.1073/pnas.0910666106. PMC 2773961. PMID 19846768.
  29. ^ a b c Prestwich GD (2008). "Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery". Acc Chem Res. 41 (1): 139-148. doi:10.1021/ar7000827. PMID 17655274.
  30. ^ a b Cassidy JW (2014). "Nanotechnology in the regeneration of complex tissues" (PDF). Bone and Tissue Regeneration Insights. 5: 25-35. doi:10.4137/BTRI.S12331. PMC 4471123. PMID 26097381.
  31. ^ Nam, Yoon Sung; Park, Tae Gwan (1999). "Biodegradable polymeric microcellular foams by modified thermally induced phase separation method". Biomaterials. 20 (19): 1783-1790. doi:10.1016/S0142-9612(99)00073-3. PMID 10509188.
  32. ^ Simon, Eric M. (1988). "NIH PHASE I FINAL REPORT: FIBROUS SUBSTRATES FOR CELL CULTURE (R3RR03544A) (PDF Download Available)". ResearchGate. Retrieved 2017.
  33. ^ Melchels F, Wiggenhauser PS, Warne D, Barry M, Ong FR, Chong WS, Hutmacher DW, Schantz JT (September 2011). "CAD/CAM-assisted breast reconstruction" (PDF). Biofabrication. 3 (3): 034114. Bibcode:2011BioFa...3c4114M. doi:10.1088/1758-5082/3/3/034114. PMID 21900731.
  34. ^ a b Jennifer Elisseeff; Peter X. Ma (2005). Scaffolding In Tissue Engineering. Boca Raton: CRC. ISBN 978-1-57444-521-3.
  35. ^ a b Lee Genee; Kenny Paraic A; Lee Eva H; Bissell Mina J (2007). "Three-dimensional culture models of normal and malignant breast epithelial cells". Nature Methods. 4 (4): 359-365. doi:10.1038/nmeth1015. PMC 2933182. PMID 17396127.
  36. ^ a b c Lai Y, Asthana A, Kisaalita WS (April 2011). "Biomarkers for simplifying HTS 3D cell culture platforms for drug discovery: the case for cytokines". Drug Discov Today. 16 (7-8): 293-7. doi:10.1016/j.drudis.2011.01.009. PMID 21277382.
  37. ^ Gustafsson, Linnea; Panagiotis Tasiopoulos, Christos; Jansson, Ronnie; Kvick, Mathias; Duursma, Thijs; Gasser, Thomas Christian; van der Wijngaart, Wouter; Hedhammar, My (16 August 2020). "Recombinant Spider Silk Forms Tough and Elastic Nanomembranes that are Protein-Permeable and Support Cell Attachment and Growth". Advanced Functional Materials: 2002982. doi:10.1002/adfm.202002982.
  38. ^ Hu, Jerry C.; Athanasiou, Kyriacos A. (April 2006). "A self-assembling process in articular cartilage tissue engineering". Tissue Engineering. 12 (4): 969-979. doi:10.1089/ten.2006.12.969. ISSN 1076-3279. PMID 16674308.
  39. ^ Lee, Jennifer K.; Huwe, Le W.; Paschos, Nikolaos; Aryaei, Ashkan; Gegg, Courtney A.; Hu, Jerry C.; Athanasiou, Kyriacos A. (12 June 2017). "Tension stimulation drives tissue formation in scaffold-free systems". Nature Materials. 16 (8): 864-873. Bibcode:2017NatMa..16..864L. doi:10.1038/nmat4917. ISSN 1476-1122. PMC 5532069. PMID 28604717.
  40. ^ Chen P, Luo Z, Güven S, Tasoglu S, Ganesan AV, Weng A, Demirci U (September 2014). "Microscale Assembly Directed by Liquid-Based Template". Advanced Materials. 26 (34): 5936-5941. doi:10.1002/adma.201402079. PMC 4159433. PMID 24956442.
  41. ^ Mironov V; Boland T; Trusk T; Forgacs G; Markwald RR (April 2003). "Organ printing: computer-aided jet-based 3D tissue engineering". Trends Biotechnol. 21 (4): 157-61. doi:10.1016/S0167-7799(03)00033-7. PMID 12679063.
  42. ^ Alta, Anthony (March 2011). "Printing a human kidney". TED.
  43. ^ Du Y, Han R, Wen F, Ng San San S, Xia L, Wohland T, Leo HL, Yu H (January 2008). "Synthetic sandwich culture of 3D hepatocyte monolayer". Biomaterials. 29 (3): 290-301. doi:10.1016/j.biomaterials.2007.09.016. PMID 17964646.
  44. ^ Atala, Anthony; Yoo, James J.; Carlos Kengla; Ko, In Kap; Lee, Sang Jin; Kang, Hyun-Wook (March 2016). "A 3D bioprinting system to produce human-scale tissue constructs with structural integrity". Nature Biotechnology. 34 (3): 312-319. doi:10.1038/nbt.3413. ISSN 1546-1696. PMID 26878319. S2CID 9073831.
  45. ^ Maciulaitis J; Deveikyte M; Rekstyte S; Bratchikov M; Darinskas A; Simbelyte A; Daunoras G; LAurinaviciene A; Laurinavicius A; Gudas R; Malinauskas M; Maciulaitis R (March 2015). "Preclinical study of SZ2080 material 3D microstructured scaffolds for cartilage tissue engineering made by femtosecond direct laser writing lithography". Biofabrication. 7 (1): 015015. Bibcode:2015BioFa...7a5015M. doi:10.1088/1758-5090/7/1/015015. PMID 25797444.
  46. ^ a b Greggio, C.; De Franceschi, F.; Figueiredo-Larsen, M.; Gobaa, S.; Ranga, A.; Semb, H.; Lutolf, M.; Grapin-Botton, A. (2013). "New 3D method used to grow miniature pancreas model". Development. 140 (21): 4452-4462. doi:10.1242/dev.096628. PMC 4007719. PMID 24130330. Retrieved 2013.
  47. ^ Greggio, C.; De Franceschi, F.; Figueiredo-Larsen, M.; Gobaa, S.; Ranga, A.; Semb, H.; Lutolf, M.; Grapin-Botton, A. (2013). "Artificial three-dimensional niches deconstruct pancreas development in vitro". Development. 140 (21): 4452-4462. doi:10.1242/dev.096628. PMC 4007719. PMID 24130330.
  48. ^ Lee, EL; von Recum, HA (2010). "Cell culture platform with mechanical conditioning and nondamaging cellular detachment". J Biomed Mater Res A. 93 (2): 411-8. doi:10.1002/jbm.a.32754. PMID 20358641.
  49. ^ a b "MC2 Biotek - 3D Tissue Culture - The 3D ProtoTissue System(TM)". Archived from the original on 28 May 2012.
  50. ^ Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA (2009). "Spheroid-based drug screen: considerations and practical approach". Nat Protoc. 4 (3): 309-24. doi:10.1038/nprot.2008.226. PMID 19214182. S2CID 21783074.
  51. ^ a b Marx, Vivien (April 2013). "A better brew". Nature. 496 (7444): 253-258. doi:10.1038/496253a. ISSN 0028-0836. PMID 23579682.
  52. ^ Zhang, Zhi-Yong; Teoh, Swee Hin (2009). "A biaxial rotating bioreactor for the culture of fetal mesenchymal stem cells for bone tissue engineering". Biomaterials. 30 (14): 2694-2704. doi:10.1016/j.biomaterials.2009.01.028. PMID 19223070.
  53. ^ Griffith Linda G., Swartz Melody A. (2006). "Capturing complex 3D tissue physiology in vitro". Nature Reviews Molecular Cell Biology. 7 (3): 211-224. doi:10.1038/nrm1858. PMID 16496023. S2CID 34783641.
  54. ^ Hiroaki Onoe, Teru Okitsu, and Akane et al. Itou. Metre-long cell-laden microfibres exhibit tissue morphologies and functions. Nature Materials, 12(6):584 - 590, 2013
  55. ^ a b Hwang J, Jeong Y, Park JM, Lee KH, Hong JW, Choi J (8 September 2015). "Biomimetics: forecasting the future of science, engineering, and medicine". International Journal of Nanomedicine. 10: 5701-13. doi:10.2147/IJN.S83642. PMC 4572716. PMID 26388692.CS1 maint: uses authors parameter (link)
  56. ^ "Scientists mimic neural tissue in Army-funded research | U.S. Army Research Laboratory". www.army.mil. Retrieved 2020.
  57. ^ a b Litschel, Thomas; Norton, Michael M.; Tserunyan, Vardges; Fraden, Seth (2018). "Engineering reaction-diffusion networks with properties of neural tissue". Lab on a Chip. 18 (5): 714-722. arXiv:1711.00444. doi:10.1039/C7LC01187C. ISSN 1473-0197. PMID 29297916. S2CID 3567908.
  58. ^ a b "Soft Robots". fradenlab. Retrieved 2018.
  59. ^ a b c d e f g h i j k l m n Umemura, Maki (3 April 2019). "Challenging the Problem of 'Fit': Advancing the Regenerative Medicine Industries in the United States, Britain and Japan". Business History. 61 (3): 456-480. doi:10.1080/00076791.2018.1476496. ISSN 0007-6791. S2CID 158171857.
  60. ^ a b c d e Bouchie, Aaron (1 December 2002). "Tissue engineering firms go under". Nature Biotechnology. 20 (12): 1178-1179. doi:10.1038/nbt1202-1178. ISSN 1546-1696. PMID 12454657. S2CID 9682305. Retrieved 2020.
  61. ^ a b c d Brown, Nik; Faulkner, Alex; Kent, Julie; Michael, Mike (1 February 2006). "Regulating Hybrids: 'Making a Mess' and 'Cleaning Up' in Tissue Engineering and Transpecies Transplantation". Social Theory & Health. 4 (1): 1-24. doi:10.1057/palgrave.sth.8700062. ISSN 1477-822X. PMC 7099299. PMID 32226319.
  62. ^ Derksen, M.H.G (2008). Engineering flesh: towards professional responsibility for 'lived bodies' in tissue engineering. Technische Universiteit Eindhoven. ISBN 978-90-386-1428-1.
  63. ^ Kent, J.; Faulkner, A.; Geesink, I.; FitzPatrick, D. (1 January 2006). "Towards governance of human tissue engineered technologies in Europe: Framing the case for a new regulatory regime". Technological Forecasting and Social Change. Technology and Social Risk. 73 (1): 41-60. doi:10.1016/j.techfore.2005.06.006. ISSN 0040-1625. Retrieved 2020.
  64. ^ Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells, OJ L, 7 April 2004, retrieved 2020
  65. ^ Faulkner, Alex; Kent, Julie; Geesink, Ingrid; FitzPatrick, David (1 November 2006). "Purity and the dangers of regenerative medicine: Regulatory innovation of human tissue-engineered technology". Social Science & Medicine. 63 (9): 2277-2288. doi:10.1016/j.socscimed.2006.06.006. ISSN 0277-9536. PMC 7130933. PMID 16905231. Retrieved 2020.
  66. ^ Vishwakarma, Ajaykumar (November 2014). Stem Cell Biology and Tissue Engineering in Dental Sciences. Elsevier, 2014. ISBN 9780123971579.

References

External links


  This article uses material from the Wikipedia page available here. It is released under the Creative Commons Attribution-Share-Alike License 3.0.

Tissue_engineering
 



 



 
Music Scenes